Skip to content
About
About Us
Team & Board
Generic Medicines
Our Members
Advocacy & Policy
Overview
Federal Advocacy
State Advocacy
Tariff & Trade
Biosimilars
GDUFA/BsUFA User Fees
IP & Patent Reform
Inflation Reduction Act
Medicaid Generics Penalty
Resources
Resource Center
Generic & Biosimilar
Medicines Savings Report
Advocacy Priorities
Biosimilars
Events
All Events
GRx+Biosims 2026
Access! 2027
About
About Us
Team & Board
Generic Medicines
Our Members
Advocacy & Policy
Overview
Federal Advocacy
State Advocacy
Tariff & Trade
Biosimilars
GDUFA/BsUFA User Fees
IP & Patent Reform
Inflation Reduction Act
Medicaid Generics Penalty
Resources
Resource Center
Generic & Biosimilar
Medicines Savings Report
Advocacy Priorities
Biosimilars
Events
All Events
GRx+Biosims 2026
Access! 2027
JOIN
SEARCH
Home
Blog
Biosimilars Council Press Releases
Blog
Blog
October 20, 2017
AAM
AAM Tells Senate: Generics Are Solution to High Drug Prices
Blog
September 22, 2017
AAM
What’s the Difference Between Generics and Brand-Name Drugs?
Blog
August 23, 2017
AAM
Five Reasons Why It’s Time to Lead on Biosimilars
Blog
July 28, 2017
AAM
How Much Did Generics Save You and Your State in 2016?
Blog
June 8, 2017
AAM
2017 Generic Drug Access and Savings in the U.S. Report
Blog
April 17, 2017
AAM
REMS Abuse Impeding Patient Access to Generic Drugs – Myths and Facts
Blog
April 6, 2017
AAM
AAM Group Letter of Support for FAST Generics Act
Blog
March 28, 2017
AAM
Recapping: The Future for Biosimilars
Blog
March 10, 2017
AAM
The Future of Biosimilars – An Atlantic Policy Briefing
Blog
February 8, 2017
AAM
2016 AAM Annual Report
Blog
January 1, 2015
Model B
Resource Guide
Load More
Resources
2025 Savings Report
2025 Advocacy Priorities
2025 First Generics White Paper
Drug Shortages White Paper
Biosimilars Patient Resource Center
Biosimilar Research & Studies
Blog
Founders Blogs
Amicus Briefs
Patient Stories
About the Association
Generic Quality
About AAM
Our Team
Our Members
Generic Medicines
Biosimilars Council
Meet Our Board
Community Commitment
Careers
Contact Us
Advocacy & Policy
Federal Advocacy
Biosimilars
GDUFA/BsUFA User Fees
Inflation Reduction Act
Intellectual Property & Patent Reform
Medicaid Generics Penalty
State Advocacy
Tariffs & Trade
Events
Access! 2026
GRx+Biosims 2026
Press Releases
JOIN
About
About Us
Team & Board
Generic Medicines
Our Members
Advocacy & Policy
Overview
Federal Advocacy
State Advocacy
Tariff & Trade
Biosimilars
GDUFA/BsUFA User Fees
IP & Patent Reform
Inflation Reduction Act
Medicaid Generics Penalty
Resources
Resource Center
Generic & Biosimilar
Medicines Savings Report
Advocacy Priorities
Biosimilars
Events
All Events
GRx+Biosims 2026
Access! 2027
JOIN
SEARCH
